⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767244 | 1.00 | — | — | |
| SCHEMBL1821046 | 0.97 | — | — | |
| SCHEMBL4444740 | 0.90 | — | — | |
| SCHEMBL5709839 | 0.83 | — | — | |
| SCHEMBL11502069 | 0.83 | CYP2D6 (0.32) | — | |
| SCHEMBL19442063 | 0.73 | CHRNA7 (0.40) | — | |
| SCHEMBL36730 | 0.73 | FDPS (0.38) | — | |
| SCHEMBL2256328 | 0.73 | FDPS (0.38) | — | |
| SCHEMBL21973884 | 0.73 | CHRNA7 (0.40) | — | |
| SCHEMBL9669427 | 0.73 | FDPS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | claimed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | claimed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | claimed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | claimed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-4404378-A | HYPOTENSIVE AGENTS; VASODILATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1983-09-13 | — | — | US | claimed |
| EP-0063747-A1 | 2-Substituted or unsubstituted aminocarbonyloxyalkyl-1,4-dihydropyridines | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1982-11-03 | — | — | EP | claimed |
| CN-101619075-B | Sulfuryl hypo-phosphono hybridation peptide and preparation method thereof | UNIV BEIJING CHEMICAL | 2012-07-25 | — | — | CN | disclosed |
| CN-101265273-B | Phosphonopeptide and preparation method thereof | UNIV BEIJING | 2011-11-09 | — | — | CN | disclosed |
| CN-101619075-A | Sulfuryl hypo-phosphono hybridation peptide and preparation method thereof | UNIV BEIJING CHEMICAL | 2010-01-06 | — | — | CN | disclosed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-0063747-A1 | 2-Substituted or unsubstituted aminocarbonyloxyalkyl-1,4-dihydropyridines | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1982-11-03 | — | — | EP | disclosed |
| US-4276296-A | Substituted benzopyrano[3,4-c]pyridines, compositions and use thereof | WARNER-LAMBERT COMPANY (US) | 1981-06-30 | — | — | US | disclosed |
| US-4242507-A | Sulfonic acid esters | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
| US-4051250-A | OXAZOLE, THIAZOLE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-09-27 | — | — | US | disclosed |
| US-3933840-A | ANTIPHLOGISTIC | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-01-20 | — | — | US | disclosed |